Biodexa Advances Serenta Phase 3 Trial in FAP
CARDIFF, U.K., August 19, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced a major recruitment milestone for its Serenta registrational...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CARDIFF, U.K., August 19, 2026 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced a major recruitment milestone for its Serenta registrational...
BOULDER, Colo., June 16, 2026 Edgewise Therapeutics has announced positive top-line results from the 12-week Phase 2 CIRRUS-HCM trial...
FRIENDSWOOD, Texas, June 16, 2026 Castle Biosciences has announced that its TissueCypher® Barrett’s Esophagus Test has surpassed 100,000 clinical...
ABBOTT PARK, Ill., May 27, 2026 Abbott has announced that the updated American Cancer Society (ACS) colorectal cancer screening...
ATLANTA, Feb. 2 2026 — The latest Cancer Facts & Figures 2026 report highlights the evolving burden of cancer...
SAN JOSE, Calif., October 7, 2025 – Anixa Biosciences, Inc. (NASDAQ: ANIX), a clinical-stage biotechnology company dedicated to cancer...
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company, announced it has filed a request for a Type C...
